FDA
-
-
-
-
-
-
-
FDA grants breakthrough therapy status to Praxis drug for rare epilepsy
-
-
-
-
-
-
-
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
-
-
-
-
-
-
-
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $315 at Needham
-
-
-
-
-
-
-
Praxis receives FDA alignment on ulixacaltamide NDA submission plans
-
328,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

